सिडनी मॉर्निंग हेराल्ड: मॉडर्न COVID-19 वैक्सीन बूस्टर खुराक 'ओमिक्रॉन के खिलाफ सुरक्षात्मक प्रतीत होता है'
प्रयोगशाला परीक्षण के बाद, डेटा से पता चलता है कि स्पाइकवैक्स (मॉडर्न) वैक्सीन के दो-खुराक प्राथमिक पाठ्यक्रम के परिणामस्वरूप ओमिक्रॉन वैरिएंट के खिलाफ एंटीबॉडी को बेअसर करने की कम पीढ़ी हुई, एक बूस्टर खुराक ने एंटीबॉडी को बेअसर करने में 37 गुना वृद्धि प्रदान की।
इन निष्कर्षों पर अधिक जानकारी के लिए नीचे दिए गए लिंक के माध्यम से पूरा लेख देखें:
मॉडर्न COVID-19 वैक्सीन बूस्टर खुराक 'ओमिक्रॉन के खिलाफ सुरक्षात्मक प्रतीत होती है'
Raising Children Network - COVID-19 vaccination and children: 5-11 years
Immunising children against COVID-19 ensures stronger, longer-lasting protection than infection does. To build the best immunity, ATAGI recommends that children aged 5 to 11 years should have a 2 dose primary course of the Pfizer COVID-19 vaccine, 8 weeks apart.
This Raising Children article developed in collaboration with MVEC explores the safety, efficacy and recommendations for immunising children aged 5 to 11 years against COVID-19.
पूरा लेख पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें:
COVID-19 vaccination and children: 5-11 years
टीकाकरण पर ऑस्ट्रेलियाई तकनीकी सलाहकार समूह (एटीएजीआई) ने कोविड-19 बूस्टर वैक्सीन के रूप में स्पाइकवैक्स (मॉडर्ना) के उपयोग पर सिफारिशें की
टीजीए से हाल ही में अनुमोदन के बाद, प्रतिरक्षण पर ऑस्ट्रेलियाई तकनीकी सलाहकार समूह (ATAGI) सिफारिश की है 18 वर्ष और उससे अधिक आयु के लोगों (गर्भवती महिलाओं सहित) के लिए COVID-19 बूस्टर वैक्सीन के रूप में स्पाइकवैक्स (मॉडर्ना) का उपयोग, जिन्होंने 5 या अधिक महीने पहले COVID-19 वैक्सीन का अपना प्राथमिक कोर्स पूरा कर लिया है। बूस्टर डोज़ प्राथमिक कोर्स के लिए उपयोग की जाने वाली स्पाइकवैक्स वैक्सीन की अनुशंसित डोज़ से आधी है।
ATAGI ने नोट किया कि पात्र जनसंख्या में ऑस्ट्रेलिया में बूस्टर टीके के रूप में उपयोग के लिए मॉडर्न और फाइजर COVID-19 टीके समान रूप से स्वीकार्य हैं।
To read ATAGI's बूस्टर फॉलो के रूप में मॉडर्न COVID-19 वैक्सीन के उपयोग पर पूर्ण विवरण नीचे दिया गया लिंक:
The Conversation: Is your child frightened of needles? Here’s how to prepare them for their COVID vaccine
Most children are fearful of needles and approximately one in five kids (19%) aged 4-6 years old experience needle phobia.
A child’s initial interaction with needles in their primary years may be formative for their relationship with immunisations throughout their lives. As such, it’s important to cultivate a safe and positive vaccination experience.
This article discusses techniques and strategies to help prepare children for vaccination, including accessing professional help from play and child life therapists for those with needle phobia.
To read the full article, please follow the link below:
Is your child frightened of needles? Here’s how to prepare them for their COVID vaccine
The Conversation: How can scientists update coronavirus vaccines for omicron? A microbiologist answers 5 questions about how Moderna and Pfizer could rapidly adjust mRNA vaccines
The new Omicron variant has raised the question of whether current COVID-19 vaccines will provide sufficient protection against infection. If the virus has changed significantly, antibodies created by the original vaccine will no longer be able to recognise and defend against the new mutated variant. Consequentially, vaccines will need to be modified by swapping out the genetic code of the original spike protein for the one found on the new variant.
This article explores the scientific process behind updating mRNA vaccines including timelines and authorization procedures.
पूरा लेख पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें:
Australian Academy of Science: COVID-19 vaccines and their long-term safety
Getting vaccinated against COVID-19 is the best way to protect ourselves and our communities. Current data and evidence confidently support the long term safety of COVID-19 vaccines.
This article discusses the various safety processes currently in place for COVID-19 vaccines to ensure that they continue to be effective in preventing severe disease.
To read the article in full, click on the link below:
COVID-19 vaccines and their long-term safety
The Conversation: COVID vaccines for 5 to 11 year old’s are inching closer. Here’s what we know so far
This week, the US Food and Drug Administration (FDA) has authorised the provisional use of the Pfizer COVID-19 vaccine in children between the age of 5 to 11 years. Children will receive two doses of the vaccine, at a reduced dose (one-third of the adult dose) administered approximately three weeks apart.
Pfizer has submitted a partial application to Australia’s Therapeutic Goods Administration (TGA) and is currently on track to supply the remaining data over the next two weeks. Once approved, the Australian Technical Advisory Group on Immunisations (ATAGI) will advise the government on timing the rollout.
Current data suggests a clear advantage to immunising children against COVID-19, including protecting them from severe complications associated with the Delta variant, and helping to minimise the spread of the virus amongst the more vulnerable in the community.
Follow this link to read the full article:
COVID vaccines for 5 to 11 year old’s are inching closer. Here’s what we know so far
Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom
Novavax has completed the rolling regulatory submission to the U.K Medicines and Healthcare products Regulatory Agency (MHRA) for authorization of the first protein-based COVID-19 vaccine.
The NVX-CoV2373 vaccine is engineered from the genetic sequence of the first strain of SARS-CoV-2. Using Novavax recombinant nanoparticle technology to generate antigen derived from the coronavirus spike protein and is formulated with Novavax patented saponin-based Matrix-M ™ adjuvant to stimulate high levels of neutralizing antibodies.
Clinical data from Phase 3 trials included over 15,000 participants and demonstrated that NVX-CoV2373 elicited a strong immune response with an overall efficacy of 89.7% as well as a favourable safety and tolerability profile.
पूरा लेख पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें:
Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom
MVEC Vodcast series - COVID-19 vaccines
जैसा कि 2020 करीब आ रहा है, आशावाद है कि SARS-CoV-2 (COVID-19) के लिए एक सुरक्षित और प्रभावी टीका जल्द ही महामारी को नियंत्रित करने के लिए अनुमोदित किया जाएगा। दुनिया भर में 200 से अधिक वैक्सीन उम्मीदवार वर्तमान में नैदानिक परीक्षणों के विभिन्न चरणों में हैं, ऑस्ट्रेलिया ने 4 अलग-अलग टीकों के साथ अग्रिम खरीद समझौतों पर हस्ताक्षर किए हैं।
हमारी 3-भाग वाली वोडकास्ट श्रृंखला में, COVID-19 टीके, डॉ. डेरिल चेंग और डॉ. डेनिएला साय चर्चा करते हैं कि इतनी कम समयावधि में एक टीका विकसित करना कैसे संभव है, नैदानिक परीक्षणों में उपयोग किए जा रहे विभिन्न वैक्सीन प्लेटफॉर्म और उनके व्यक्तिगत फायदे और नुकसान , साथ ही विभिन्न प्राथमिकता समूहों को टीकाकरण की पेशकश की जाएगी। डेरिल और डेनिएला क्लिनिकल परीक्षणों के प्रारंभिक परिणामों पर स्पर्श करते हैं और वे हमें टीके की सुरक्षा और प्रभावशीलता के संदर्भ में दिखाते हैं, साथ ही चल रही सुरक्षा निगरानी पर भी चर्चा करते हैं जो एक बार उपयोग के लिए एक वैक्सीन को मंजूरी दे दी जाती है।
You can view the vodcasts via the link below:
Final episode of COVID19 Road to a vaccine: Professor Walter Orenstein
In the final episode of this podcast series our host, Associate Professor Nigel Crawford, speaks with Professor Walter Orenstein. Dr Orenstein is a Professor of Medicine, Epidemiology, Global Health and Paediatrics at Emory University; Associate Director of the Emory Vaccine Center and the Director of Emory Vaccine Policy and Development. An expert in vaccinology, Dr Orenstein has worked at the US Centers for Disease Control and Prevention, Director of the United States Immunisation Program and is a current member of several WHO groups. Further to this he is the co-editor of the vaccine textbook, Plotkin’s Vaccines, 7वां edition. In this episode they discuss:
- Lessons that can be learnt from Plotkin’s Vaccines in the setting of the SARS-CoV-2 pandemic and development of vaccines
- Recent press releases showing promising early results from two mRNA COVID-19 vaccine candidates developed by Pfizer/BioNTech and Moderna
- The critical role of ongoing monitoring for safety and effectiveness of vaccines once they are in use
- The likely highest priority groups when vaccines do become available
- The role of children in SARS-CoV-2 transmission and whether or not they need to be vaccinated
- The importance of a correlate of protection in SARS-CoV-2 vaccines
- The need to monitor for vaccine associated enhanced disease (VAED)
- The importance of immunisation providers supporting reports of adverse events following immunisation (AEFI)
- The importance of communication in supporting vaccine acceptance and uptake
- Key next steps on the road to a COVID-19 vaccine: a better understanding of how many doses are required and when, a prioritisation process so the vaccines can be used most effectively (with a clear allocation system); and communicating to the public that social distancing and wearing a mask will be ongoing for some time as a level of normality won’t be reached immediately, even with the exciting new efficacious COVID-19 vaccines
लिंक:
- Plotkin’s Vaccines, 7वां ed
- Pfizer/BioNTech conclude phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints
- Moderna’s COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the phase 3 COVE study
आप यहां एपिसोड सुन सकते हैं: